ACADIA Pharmaceuticals Inc. (ACAD) Key Statistics & Financial Ratios

ACADIA Pharmaceuticals Inc. (ACAD) — Price $27.83 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for ACADIA Pharmaceuticals Inc. (ACAD). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis.

Stock Data

Price$27.83
Market Cap$4.8B
Enterprise Value$4.40B
Beta0.83
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio12.10
Price / Book3.57
P/S4.09
EV/EBITDA37.93
EV/Sales3.87
EV/FCF25.26
P/FCF26.73
Earnings Yield8.05%
FCF Yield3.70%
Dividend Yield0.00%

Profitability

Gross Margin91.13%
EBIT Margin9.14%
EBITDA Margin10.20%
Operating Margin7.59%
Net Margin33.42%
Return on Equity32.39%
Return on Assets21.83%
Return on Invested Capital6.19%
Return on Capital Employed6.25%

Financial Health

Current Ratio3.39
Quick Ratio3.30
Cash Ratio1.07
Debt / Equity0.06
Debt / Assets4.24%
Net Debt / EBITDA-2.68
Interest Coverage0.00

Per-Share Data

Revenue per share6.64
Book Value per share7.61
Cash per share5.57
FCF per share1.02
Tangible Book Value per share7.01
Dividend per share0.00

Related companies: ADMA · BLTE · CRNX · DYN · IMVT · LGND · MIRM

Explore sector: Healthcare · Biotechnology

More sections of ACAD: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks